Glabridin, a Bioactive Flavonoid from Licorice, Effectively Inhibits Platelet Activation in Humans and Mice

• Published in: International journal of molecular sciences 2022-10, Vol.23 (19), p.11372
• Main Authors: Chung, Chi-Li, Chen, Jui-Hsuan, Huang, Wei-Chieh, Sheu, Joen-Rong, Hsia, Chih-Wei, Jayakumar, Thanasekaran, Hsia, Chih-Hsuan, Chiou, Kuan-Rau, Hou, Shaw-Min
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; Abnormalities; AKT protein; Blood clots; Blood platelets; Calcium (intracellular); Calcium ions; Calcium mobilization; Cardiovascular diseases; Cell growth; Chemical compounds; Collagen; Diabetes; Diabetes mellitus; Flavonoids; Glycogen; Glycogen synthase kinase 3; Glycogens; Hemostasis; Hemostatics; Kinases; MAP kinase; Mortality; NF-κB protein; P-selectin; Pharmacology; Phospholipase C; Phosphorylation; Platelet aggregation; Protein kinase C; Proteins; Thrombin; Thromboembolism; Thrombosis; Thromboxane A2
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms231911372

Platelets are crucial for hemostasis and arterial thrombosis, which may lead to severe cardiovascular diseases (CVDs). Thus, therapeutic agents must be developed to prevent pathological platelet activation. Glabridin, a major bioalkaloid extracted from licorice root, improves metabolic abnormalities (i.e., obesity and diabetes) and protects against CVDs and neuronal disorders. To the best of our knowledge, no studies have focused on glabridin’s effects on platelet activation. Therefore, we investigated these effects in humans and mice. Glabridin exhibited the highest inhibitory effects on collagen-stimulated platelet aggregation and moderate effects on arachidonic-acid-stimulated activation; however, no effects were observed for any other agonists (e.g., thrombin or U46619). Glabridin evidently reduced P-selectin expression, ATP release, and intracellular Ca2+ ([Ca2+]i) mobilization and thromboxane A2 formation; it further reduced the activation of phospholipase C (PLC)γ2/protein kinase C (PKC), phosphoinositide 3-kinase (PI3K)/Akt/glycogen synthase kinase-3β (GSK3β), mitogen-activated protein kinase (MAPK), and NF-κB. In mice, glabridin reduced the mortality rate caused by acute pulmonary thromboembolism without altering bleeding time. Thus, glabridin effectively inhibits the PLCγ2/PKC cascade and prevents the activation of the PI3K/Akt/GSK3β and MAPK pathways; this leads to a reduction in [Ca2+]i mobilization, which eventually inhibits platelet aggregation. Therefore, glabridin may be a promising therapeutic agent for thromboembolic disorders.